Market Analysis: Veterinary/Animal Vaccines Market on the Rise

The launch of the vaccine named, Vanguard CIV H3N2/H3N8 Vaccine, was announced in December 2017 by Zoetis. This was the most recent vaccine in the list of the company's canine influenza vaccine portfolio. Such initiatives taken by companies towards the launch of vaccines to protect animals from various diseases is promoting the growth of the global veterinary vaccines market, predicts Fortune Business Insights in their new report. According to the report, the market is anticipated to rise from a value of USD 9.75 Billion in 2018 to USD 16.01 Billion by 2026. The forecast period is set from 2019 to 2026 and the market is expected to rise at a CAGR of 6.4%.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/veterinary-animal-vaccines-market-101532

Leading Players operating in the Veterinary / Animal Vaccines Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

o NEOGEN CORPORATION
o Eli Lilly and Company
o Elanco
o Merial
o ImmuCell Corporation
o Ceva
o Intervet Inc. (Merck Animal Health)
o Boehringer Ingelheim International GmbH
o Virbac
o Zoetis

Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Major Animal Diseases by Countries
4.2. Livestock and Companion Animal Ownership Patterns
4.3. Recent Industry Developments such as Mergers & Acquisitions
4.4. Regulatory Scenario in Key Countries
4.5. Technological Advancements in Animal Immunization
4.6. Overview of Novel Vaccine Delivery Modes
4.7. Key Strategies Adopted by Market Leaders
5. Global Veterinary Vaccines Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast - By Product
5.2.1. Inactivated
5.2.2. Live Attenuated
5.2.3. Recombinant
5.2.4. Others
5.3. Market Analysis, Insights and Forecast - By Animal
5.3.1. Companion
5.3.2. Livestock
5.4. Market Analysis, Insights and Forecast - By Route of Administration
5.4.1. Oral
5.4.2. Parenteral
5.4.3. Others
5.5. Market Analysis, Insights and Forecast - By Distribution Channel
5.5.1. Veterinary Hospitals
5.5.2. Veterinary Clinics
5.5.3. Pharmacies & Drug Stores
5.5.4. Others
5.6. Market Analysis, Insights and Forecast - By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Veterinary Vaccines Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis - By Product
6.2.1. Inactivated
6.2.2. Live Attenuated
6.2.3. Recombinant
6.2.4. Others
6.3. Market Analysis - By Animal
6.3.1. Companion
6.3.2. Livestock
6.4. Market Analysis - By Route of Administration
6.4.1. Oral
6.4.2. Parenteral
6.4.3. Others
6.5. Market Analysis - By Distribution Channel
6.5.1. Veterinary Hospitals
6.5.2. Veterinary Clinics
6.5.3. Pharmacies & Drug Stores
6.5.4. Others
6.6. Market Analysis - By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Veterinary Vaccines Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis - By Product
7.2.1. Inactivated
7.2.2. Live Attenuated
7.2.3. Recombinant
7.2.4. Others
7.3. Market Analysis - By Animal
7.3.1. Companion
7.3.2. Livestock
7.4. Market Analysis - By Route of Administration
7.4.1. Oral
7.4.2. Parenteral
7.4.3. Others
7.5. Market Analysis - By Distribution Channel
7.5.1. Veterinary Hospitals
7.5.2. Veterinary Clinics
7.5.3. Pharmacies & Drug Stores
7.5.4. Others
7.6. Market Analysis - By Country/ Sub-Region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Scandinavia
7.6.7. Rest of Europe
8. Asia Pacific Veterinary Vaccines Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis - By Product
8.2.1. Inactivated
8.2.2. Live Attenuated
8.2.3. Recombinant
8.2.4. Others
8.3. Market Analysis - By Animal
8.3.1. Companion
8.3.2. Livestock
8.4. Market Analysis - By Route of Administration
8.4.1. Oral
8.4.2. Parenteral
8.4.3. Others
8.5. Market Analysis - By Distribution Channel
8.5.1. Veterinary Hospitals
8.5.2. Veterinary Clinics
8.5.3. Pharmacies & Drug Stores
8.5.4. Others
8.6. Market Analysis - By Country/ Sub-Region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
Continued...

Market Segmentation:
By Product
o Inactivated
o Live Attenuated
o Recombinant
o Others
By Animal
o Companion
o Livestock
By Route of Administration
o Oral
o Parenteral
o Others
By Distribution Channel
o Veterinary Hospitals
o Veterinary Clinics
o Pharmacies & Drug Stores
o Others
By Geography
o North America (U.S. and Canada)
o Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
o Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
o Latin America (Brazil, Mexico, and Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.